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Abstract—Targeted drug delivery system is believed as one of
the most promising solutions for cancer treatment due to its low-
dose requirement and less side effects. However, both passive tar-
geting and active targeting rely on systemic blood circulation and
diffusion, which is actually not the real “active” drug delivery. In
this paper, an ant-behavior inspired nanonetwork composing of
intelligent nanomachines is proposed. A big intelligent nanoma-
chine take small intelligent nanomachines and drugs to the
vicinity of of the tumor area. The small intelligent nanomachines
can coordinate with each other to find the most effective path
to the tumor cell for drug transportation. The framework and
mechanism of this cooperative network are proposed. The route
finding algorithm is presented. The convergence performance is
analytically analyzed where the influence of the factors such as
molecule degradation rate, home-destination distance, number
of small nanomachines to the convergence is presented. Finally
the simulation results validate the effectiveness of the proposed
mechanism and analytical analysis.
Index Terms—ant, NanoNet, molecular communication, tar-
geted drug delivery, cancer therapy
I. INTRODUCTION
Cancer, which involves the abnormal cell growth, is among
the leading causes of death for years worldwide. Once it goes
into stage IV with metastasis, cancer/tumor cells spread to
other parts of body via lymphatic or blood vessels [2], then
the mortality rate becomes significantly higher. Chemotherapy
is a widely used cancer treatment method for many types of
cancers, by which the anti-cancer drugs are introduced into the
blood stream, address cancer, and stop cancer cell division
by killing them [3]. The major drawbacks of chemotherapy
include the inefficacy and the serious side-effect where the
drugs not only kill cancer cells, but also kill other normal
cells.
Targeted drug delivery is a method of delivering medication
to specific parts of the body where there is solely diseased
tissue, thereby avoiding interaction with healthy tissue [4]–[7].
In this way, the targeted delivery can improve efficacy while
reducing side-effects. Targeted drug delivery is classified as
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passive targeting and active targeting [8]. In passive targeting,
by cloaking the drug-loaded nanoparticle with some sort of
coating, the drugs are able to stay in circulation for a longer
period of time. Some research might study the optimization
issue of release pattern [9]. Active targeting of drug-loaded
nanoparticles enhances the effects of passive targeting to
make the nanoparticle more specific to a target site [10].
The examples include the use of cell-specific ligands or pH
responsive materials [11].
We found that no matter passive targeting or active targeting,
the movement of the drug-loaded nanoparticles is passive,
relying on systemic blood circulation and diffusion, which
makes the drug delivery less efficient and slow. It is expected
that the nanorobot can be used for targeted drug delivery,
which can actively move close to the target [12]. Several
studies have been conducted to design nanorobots for drug
delivery function. For example, a self-propelled polymer-based
multilayer nanorobots with porous membrane was proposed
for drug release [13]. A chemically powered nanomotor for
nanoscale cargo delivery was proposed in [14]. A magnetic
micromotor vehicle for transporting durg-loaded magnetic
polymeric particles was proposed in [15]. Reference [16]
proposed a ultrasound driven nanowire motors which could
perform drug delivery by a light-triggered release. Those liter-
ature do propose mechanisms for active moving of nanorobots.
However, how to control the nanorobot is still a challenge.
Some papers did not mention the methods, and some other
papers gave the control mechanisms but it is obviously difficult
for implementation. Moreover, due to the limited size, at least
in its early stage the nanorobot would be resource constraint
with simple intelligence, and can only carry a tiny amount of
drugs.
For the ant colony [17]–[19], each individual ant only has
very limited resources and ability, but the groups of the ants
can form remarkable collective intelligence. Whats more, by
laying down molecules along the trail of the ants, an optimal
trail to the destination can be established. Inspired by that,
in this paper we propose a similar nanorobot network named
NanoNet, for the targeted drug delivery in cancer therapy. The
aim is that by the collaboration of the nanorobot/nanomachines
via non-diffusive molecular communication [20]–[22], the
formed NanoNet can intelligently find the best path to the
tumor cells and transport drugs. Compared with our previous
work [1], more details about the mechanism is presented,
and a complete analysis and discussion is added. The major
contributions of this paper include:
1) A complete framework of NanoNet for intelligent tar-









Fig. 1: Framework of NanoNet.
delivery along blood vessels or and through interstitial
fluids.
2) Under the proposed NanoNet framework, the mechanism
and algorithm for small nanomachines via non-diffusive
molecular communication to find the destination, i.e., the
tumor cell, is proposed and presented in detail.
3) The convergence performance for intelligent small
nanomachines to find the best path for drug delivery is
analytically analyzed, and the discussion is presented.
4) The effectiveness of the proposed mechanism and algo-
rithm and the convergence conditions are evaluated by
simulations.
The rest of the paper is organized as follows. In Section II,
we present the framework and the system model. Section III
presents the proposed mechanism of the collective ant behavior
to active drug delivery. In Section IV, the convergence to the
shortest path is analytically analyzed. The simulation results
are provided in Section V. Finally, Section VI concludes the
paper.
II. FRAMEWORK AND SYSTEM MODEL
The overall goal of NanoNet is to deliver drugs to the
destination, i.e., the tumor cell. In the proposed framework,
the entire delivery process is composed of two steps, as shown
in Fig. 1. For the first step, a big nanomachine, which contains
M small nanomachines and drugs, moves in the blood vessel
and is anchored on the blood vessel wall in the vicinity of the
tumor cell. It is assumed that the big nanomachine is injected
into the blood vessel as close to the tumor as possible. The
position of the tumor could be found by existing techniques
such as MRI or mobile nanosensors [23]. The tumor cells
discrete more microvesicles, e.g., exosomes, than normal cells,
which can be used as a sign for the possible existence of the
tumor cells [24]. Therefore, the big nanomachine can stop
and anchor itself when it senses abnormally high exosomes.
For the second step, the small nanomachines carry drugs
and start moving from the big nanomachine, which is named
as “home”, to the destination through interstitial fluids and
extracellular fluid among cells [25], [26]. Because there exist
specific detectable proteins on the surface of tumor cell [27],
the small nanomachine can use this kind of proteins to locate
the destination when they move. The small nanomachines go
back to the home, carry drugs, move to the destination for
drug delivery again.
The diameter of blood vessels varies for different parts of
human body. It ranges from about 25 millimeters for the aorta
to only 8 micrometers in the capillaries [28]. The extracellular
space between cells ranges from several nanometers to tens of
nanometers [29], [30]. So in this paper it is assumed that the
size (diameter) of the big nanomachine is 6-8µm, which is
close to the size of red cells. It can go through blood vessels,
but cannot go into the interstitial fluid from the blood vessel. It
is assumed that the size (diameter) of the small nanomachine
is around 10 nm, to make sure it can go through most of
extracellular space among cells. It is also assumed that the
big nanomachine does not affect the normal propagation of
blood in the blood vessels, including hindering the normal
flow of blood cells or plasma, or forming clots close to the
blood vessel walls.
Because the small nanomachines are more size constraint
than the big nanomachine, and they need to coordinate with
each other intelligently to find the best route between the home
and the destination, which is much complicated, therefore, in
this paper we focus on the mechanism of the second step.
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Fig. 2: An example of lattice graph representing the path
model. The “home” is at (2,2) and the “destination” is at (9,9).
Euclidean space R2. An example is shown in Fig. 2. The
grid is considered as a pathway among cells. The vertex
is denoted by (i, j), where i and j are the x-coordinate
and y-coordinate. The physical distance between the adjacent
vertices is assumed to be 1, unit distance. Because the space
beyond blood vessels is filled with interstitial fluids and
extracellular matrix, which pose hurdles in the movements of
the drug-carrying nanomachines, it is assumed that the edges
between the adjacent vertices in the graph can have different
weights. In the graph, it is assumed that there is one home
with the location of (xh, yh) and one destination with the
location of (xd, yd).
In the beginning, M small nanomachines carrying drugs
start to move from the home. The aim of these nanomachines
is to arrive at the destination, e.g. tumor location, and release
drugs there. Then the nanomachines go back to the home, load
drugs again, and repeat the drug delivery process.
Because the small nanomachines are size constraint and
resource constraint, they have very limited ability. They also
do not know the path from home to destination in advance.
Therefore, finding a path to the destination, especially, finding
the optimal path to the destination, is a challenge.
It is assumed that the small nanomachines can release two
types of adhesive molecules, named home molecules and
destination molecules. These molecules are assumed to be
non-diffusive, i.e., once they are released by nanomachines,
they cannot diffuse. These kind of adhesive surface binding
molecules exist widely in biology. The examples of the
adhesive molecules include collagen, elastin, fibronectin and
laminin [21], [31], [32]. Because the molecules are adhesive,
they will almost not undergo thermal diffusion, and are less
affected by the components in the interstitial fluid. In this
paper, the system is assumed to be discrete both spatially and
temporally. Spatially, the molecules can only be laid down at
the vertices. Consecutive vertices are neighbors. Temporally,
the unit of time is one iteration where each individual small
nanomachine move one step from one vertex to its neighboring
vertex.
For a specific location (i, j), the concentration of home
molecules after the nth iteration is denoted by φi,j(n). Simi-
larly, the concentration of destination molecules at the location
(i, j) after the nth iteration is denoted by ψi,j(n). The same
types of molecules released by different nanomachines can be
mixed together, and the total concentration is the sum of the
molecular concentrations released by different nanomachines.
Home molecules and destination molecules do not influence
or react with each other.
It is assumed that the molecules degradate over time with
degradation rate ρ [33]. For example, if there is no newly laid
down molecules, then from the nth iteration to (n+1)th iter-
ation, the concentration of home molecules can be expressed
as
φi,j(n+ 1) = (1− ρ)φi,j(n)− η, (1)
where η is assumed to be a zero-mean Gaussian random
variable. The degradation is very important for the small
nanomachines to find the shortest path between home and
destination. This will be discussed in the latter part of this
paper in detail. It is also assumed that the nanomachines have
the same moving speed, and they do not collide with each
other when the nanomachines meet on the route.
III. PROPOSED MECHANISM AND ALGORITHM
In this section, the mechanism of the collaboration of small
nanomachines to find the route between home and destination
is proposed.
In the beginning, M small nanomachines carrying drugs
start to move from the home at the same time. Initially
they wander randomly on the lattice graph. The nanoma-
chines release home molecules when they travel from home
to destination. The home molecules will later be used by
nanomachines to find the route from the destination to home.
In our proposed scheme, the nanomachine releases Q home
molecules at home position, and releases Q − q molecules
after it moves one step away from home. Then after n step
movement, that nanomachine will release Q − nq molecules
at its location. If Q− nq < 0, then the nanomachine will not
release molecules. The reason that the nanomachine releases
less home molecules as it goes away from the home is that it
has less information of the home as it goes further away from
the home. It has less confidence about where the home is. To
be a by-product, a concentration gradient is formed based on
the proposed molecule releasing rule. The nanomachine will
find its way to home based on the positive gradient direction.
The molecules are non-diffusive [20], [21] and degradate over
time.
Once the nanomachines arrive at the destination, they unload
the drugs, and go back to the home for the next round drug
movement. The nanomachines do not move randomly as their
first time travel from home to destination. As mentioned
earlier, they will follow the positive gradient direction of home
molecules along the path to go back to the home, provided that
there are molecules on the path. It is possible that when the
nanomachine goes from home to destination, before it arrives
at the destination, Q − nq already becomes negative. Then
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there is no molecule releasing for the nanomachine’s following
movement until it arrives the destination.
The rule for selecting next step movement for a nanoma-
chine which is at certain vertex in the lattice graph is like
this: assuming that the nanomachine has three possible options
of moving direction for the next step, i.e., left, right, and
front (sometimes it may have two possible options when it
is on the edge of the graph. The logic of the rule is similar).
Assuming that the real concentrations of the corresponding
neighboring vertices are Cl, Cr, Cf , then the probabilities
that the nanomachine move to left vertex, right vertex, and
front vertex are expressed as
Pl =
Cl








(Cl + Cr + Cf )
.
(2)
The nanomachine will choose one moving direction based on
probabilities.
Similar to the movement from home to destination, the
nanomachines release destination molecules when they move
from destination to home. They also reduce the amount of
molecules with the reducing speed q molecules/step as they
move.
The drug movement is performed repeatedly until the end.
It should be noted that the home molecules and destination
molecules do not influence each other. They can co-exist
without reaction. And the nanomachines have the ability to
differentiate that two types of molecules and detect their
concentrations within one-step distance, i.e., the position the
nanomachine stands on and its neighboring positions on the
graph.
After the nth round of iterations, the concentrations for
home molecules and destination molecules at the location
(i, j) can be expressed as











where τmi,j(n) and δ
m
i,j(n) represent the concentrations of home
molecules and destination molecules released by nanomachine
m at location (i, j) at the nth iteration. ξ is the noise term for
degradation of the destination molecules.
The algorithm for the route selection by small nanomachines
is shown in Algorithm 1.
For the probability calculation in step 9, in the initial phase
when the concentrations of the next possible positions are all
zero, or in the middle phase, when the concentrations of the
next possible positions are the same, then these positions in
each direction calculation have equal probabilities.
Because the small nanomachines move between home and
destination back and forth, they lay down molecule trails. A
shorter path, would get marched over more frequently (the
Algorithm 1 The algorithm of small nanomachines
1: initialization
2: while drugs available do
3: for k=1:nAnt do




7: for k=1:nAnt do ⊲ Nanomachine’s move
8: Obtain the concentration of left, right, and front
location
9: Calculate the probability for moving direction
based on (2)




13: for k=1:nAnt do ⊲ Check if arriving at home or dest
14: if ant(k).Position==destination then
15: ant(k).ToDestination=0;
16: ant(k).Step=0;





22: for k=1:nAnt do ⊲ Concentration update
23: if Q-ant(k).Step× q<0 then τ = 0
24: elseτ = Q− ant(k).Step× q
25: end if
26: Update concentration based on (3)
27: end for
28: end while
nanomachine which follows shorter path will come back ear-
lier than others), and thus the molecule density becomes higher
on shorter paths than longer ones. If other nanomachine find
such a path, they are likely not to keep traveling at random,
but instead to follow the trail, returning and reinforcing it
if they eventually find the destination. The positive feedback
eventually leads to the nanomachines following a shortest path.
The next section will give analytical analysis and convergence
discussion.
IV. ANALYTICAL ANALYSIS AND CONVERGENCE
DISCUSSION
The proposed mechanism in Section III actually forms an





where d(path) is the distance for certain path and P is the space
of all possible paths. The small nanomachines are autonomous
computational entities and they communicate by molecular
communication via the released non-diffusive molecules.
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Next, the conditions for the convergence is discussed. There
are three levels regarding the convergence in our scenario: as
time goes to infinity, 1) no single path is formed; 2) a single
path is formed, but not the shortest path between home and
destination; 3) a single path is formed, which is the shortest
path (optimal solution) between home and destination. These
three conditions correspond to not converge, converge to some
path but not the shortest path, and converge to the shortest
path.
Proposition 1 The path formed by the nanomachines will not





holds, where N is the length of
the shortest path.
Proof As mentioned in Section III, Q is the amount of
molecules a single nanomachine releases when it is at home
or destination before it starts moving to the other end. q is
the difference of the amount of molecules the nanomachine
releases for one step moving. For example, a nanomachine
which starts at home towards destination, releases Q molecules
at the home location, and after one step movement, it releases
Q − q molecules. after n step movement, that nanomachine
will release Q− nq molecules at its location.
If the nanomachine can go from the destination to home
following the trails of molecules along the positive concentra-
tion gradient direction, two conditions must be satisfied: 1) the
shortest distance between the home and the destination cannot
be too long that there is no molecule released by the nanoma-
chine along the path from the home to the destination, 2) the
degradation rate cannot be too fast that the correct molecular
concentration gradient towards the home or destination does
not exist.
For the first condition, Q − (N − 1)q is the amount of
molecules released by the nanomachine which follows the
shortest path from home to destination just one step before
arriving at the end. The following should hold
Q− (N − 1)q > 0, (5)
so that when the nanomachine returns, it has molecule trail
information to follow. Therefore, the condition that the path
will not converge can be expressed as
Q− (N − 1)q ≤ 0. (6)







For the second condition, when the nanomachine moves
after n step movement from home or destination, it will release
Q−nq molecules. After it moves one more step and arrives at
the (n+1)th location, it will release Q− (n+1)q molecules.
At the same time, molecules at the last location (the location
it arrives after the nth step) degradatete with rate ρ, so the
concentration becomes (1−ρ)(Q−nq). The convergence may
be achieved if
(1− ρ)(Q− nq) > Q− (n+ 1)q, (8)
is satisfied, i.e., the molecular concentration of the location
closer to the origin (home or destination) is greater than that





, n = 0, 1, ..., N. (9)
Equation (9) has to be satisfied for all possible values of
n. The minimum value of q
Q−nq
is obtained when n = 0.










Combing (7) and (11), the condition that the path formed









It should be noted that (12) is the condition that the path
does not converge, but it does not mean that it will converge
once the complement of (12) is satisfied.
Next, we would like to discuss when the precondition







is satisfied, what else condition should be satisfied for the
convergence to optimal solution (shortest path).
Let us consider the scenario with only one nanomachine
in the environment first, i.e., M = 1. We define Self-shortest
path as below.
Definition 1 Self-shortest path is defined as a path where
there are no two separate points (at least one point in the mid-
dle) in the path, which are the same vertex or the neighboring
vertices on the lattice graph.
An example is shown in Fig. 3. An example of the self-
shortest path is shown in (a). If a small nanomachine goes from
(1, 2) to (6, 2) as the red line in (a), at the same time laying
down tracking molecules, then it has only one route, the same
route, to go back by following the tracking molecules. An
example of a path which is not a self-shortest path in shown
in (b). This is because the vertex (3, 2) and (4, 2), which are
separate points on the path as defined, are neighboring vertices.
If a small nanomachine goes from (1, 2) to (6, 2) as the red
line in (b), at the same time laying down tracking molecules,
then when it goes back to (1, 2), it would follow the red route
shown in (c) because of the gradient.
Two cases will be discussed below:
Case 1: the first round path of the nanomachine from home
to destination is a self-shortest path. In this case, according to
the rule selection in (2), the return path from destination to
home will be the same as the path from home to destination,
and the nanomachine will follow this path forever. This first
round path from home to destination is totally random, and
has a very low probability to be the shortest path.
Case 2: the first round path of the nanomachine from home
to destination is not a self-shortest path. In this case, when
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(a) An example of the self-shortest path.












(b) An example of a path which is not a self-shortest
path.












(c) The shortest path if a small nanomachine’s route is
the red line in (b).
Fig. 3: Explanation of the self-shortest path. (a) An example
of the self-shortest path. (b) An example of a path which is
not a self-shortest path in shown. (c) The shortest path if a
small nanomachine’s route is the red line in (b).
the nanomachine moves back from the destination to home,
it will more likely choose shorter path at the point which
makes the first round path from home to destination not self-
shortest. The shorter path will be obviously different from
the first round path from home to destination. The reason
the shorter path will be chosen is that when the nanomachine
faces two direction options, the concentration from the shorter
path’s point is larger than that from the longer path’s point.
This is because of the mechanism of gradually reducing
release of molecules as the nanomachine moves. After that,
the probability the nanomachine chooses the shorter path
increases for the following back and forth between home and
destination. As time goes to infinity, the nanomachine will




Pr(Stephtod = R) = 1, R ≥ N, (14)
where i is the number of iteration, Pr() represents probability,
and Stephtod is the number of steps from home to destination,
R is a value greater than or equal to N . The final path in Case
2 has higher probability to be the shortest path than in Case
1.
A short proof of convergence to a single path in probability
is given below.
It is assumed that there are two possible paths the nanoma-
chine can walk through, the length of path1 is shorter than
that of path2, denoted by path1 < path2. The concentration
of the first movement into path1 is denoted as Cp1, and the
concentration of the first movement into path2 is denoted as
Cp2. There is no constraint if the concentration of the first
movement into path1 is larger than that of path2 or not. The











If path1=path2, then the amounts of molecules released at
the end of path1 and path2 are the same. Considering the
entry probability of path1 and path2, the ratio of the amounts






, will be the same as
Cp1
Cp2
. However, path2 is assumed
to be longer than path1, so the amounts of molecules released








This means that the nanomachine will have more chance to
go back from path1 than from path2. As the nanomachines go
back and forth between home and destination, there will be
more and more molecules laying down on path1. Finally, the
convergence is achieved. 
Next, we discuss the scenario where more than one nanoma-
chine are in the environment. More nanomachines will in-
crease the solution space for the first round movement from
home to destination. More nanomachines will also accelerate
the convergence for the whole NanoNet.
No matter one nanomachine scenario or multiple nanoma-
chine scenario, the first round movement of the nanomachine
from home to destination is the key factor for the convergence.
It determines the solution space. If this solution space contains
the optimal solution, then the shortest path will be achieved in
probability as time goes to infinity. If the solution space after
the first round movement from home to destination does not
contain the optimal solution, then the shortest path will never
be explored. An example is shown in Fig. 4. In that figure,
assuming a nanomachine goes from one red point to another
for the first round movement. The blue and red points represent
the whole solution space on which the nanomachine goes.
We can easily find that the solution space does not include
a shortest path between the two red points.
If the number of nanomachines goes to infinity, then the
probability that the first round movement contains the shortest
7
Fig. 4: An example showing that a solution space does not
include optimal solution.
TABLE I: Simulation Parameters
Parameters Value
Lattice graph range 10×10
Shortest path length N 3 - 15
Maximum molecule release Q N − 1 - 100
Number of small nanomachines M 1 - 50
degradation rate ρ 0 - 0.9
Decremental released molecules q 1
path tends to 1. Then as time goes to infinity, the whole
network will converge to the shortest path in probability, which







= 1, m = 1, 2, ...,M
(16)
The convergence is also related to our proposed mechanism.
In our proposed mechanism, if the nanomachine does not go
through certain vertex in the graph, then according to (2), it
will have no chance to go through that vertex later. Then it
may lose the chance to achieve the shortest path. But if the
mechanism can give a small probability for the nanomachines
to go into that vertex even if that vertex is not passed by the
nanomachine, then the convergence to the shortest path will
definitely happen.
V. SIMULATION RESULTS
In this section, simulations are performed by MATLAB
to validate the effectiveness of the proposed mechanism as
well as the analytical analysis and discussion. The conditions
for the convergence rely on several factors, such as molecule
degradation rate, home-destination distance, the number of
nanomachines, etc. We will discuss the influence of those
factors to the convergence performance.
A 10×10 lattice graph is used. In the simulations, the
position of the home and destination is determined first. The
shortest path length is set to 10-15. The maximum molecule
release Q is set to N to 100. The number of small nanoma-
chines is set to 1 to 50. Then for the fixed number of small
nanomachines, the simulation experiments are run 100 times.
For each time, no more than 10000 iterations is conducted. The
iterations end if stable convergence is seen. The degradation
rate is set between 0 and 0.9. Simulation parameters are shown
in Table 1.
Fig. 5 shows the molecule concentration summation of the
two kinds of molecules on the trails for different iterations
and different degradation rates for a single simulation run.
The degradation rate ρ is set as 0.01, 0.02, and 0.03. These
values are determined under the condition in (13). It can be
seen that after a number of iterations, the single path is formed
clearly, which is the shortest path. It should also be noted that
even with the same shortest path length, the path itself may
be different. We can also see that when ρ = 0.03, after 700
iterations, the path converges. But when ρ = 0.02, after 700
iterations, the path does not converge. when ρ = 0.02, after
2000 iterations, the path converges. But when ρ = 0.01, after
3000 iterations, the path does not converge.
This phenomena can also be reflected in Fig. 6. In Fig. 6, it
can be seen that all the three curves finally converge to a stable
value. The curve with larger ρ converges faster than the other
two curves with relatively small ρ value. The reason is because
if ρ is larger, then the concentration on the longer path will
degradate faster. It help accelerating the convergence. If ρ is
smaller, for example the solid blue curve, it can be seen that it
takes nearly 8000 iterations to converge. Because of the route
selection rule in (2), even if the nanomachine goes into the
shorter path, it will still go into longer path. This is because
the molecule concentration of the vertices on the longer path
still has a relatively high value.
Fig. 7 shows Iterations versus degradation rate for different
home-destination distances. It can be seen that as the increase
of the home-destination distance, the iteration for the conver-
gence increases. This is because the nanomachines need more
movement from home to destination or from destination to
home. It can also be seen that the increase of ρ leads to less
iterations for convergence. The reason is that bigger ρ means
the trailing molecules degradate faster, then the molecules on
the less passed route will degradate more quickly and the
shortest path trail will be established more quickly. Then the
less iterations are needed for the convergence.
Fig. 8 shows the iteration versus number of small nanoma-
chines for different home-destination distances. We can con-
clude from the figure that the increase of the number of small
nanomachines leads to faster convergence. The reason might
be: 1) more nanomachines have more chance to explore the
solution space in the first round movement from home to
destination. This may lead to smaller iterations to achieve con-
vergence. 2) more nanomachines will release more molecules
during their movement between the home and destination.
This will accelerate the convergence. It can be also seen that
after the number of the small nanomachines reaches 30, the
iterations becomes stable. This reflects that the influence of
reason 2 to the convergence is not as significant as reason 1.
Fig. 9 shows the maximum molecule release Q versus
home-destination distance N . This result comes from (13). Q
8
Fig. 5: Molecule concentration on lattice graph for different iterations and different degradation rates.































Fig. 6: Convergence length versus iterations: an example.
needs to be large enough so that there exist molecules on the
shortest trail between the home and destination. In this figure,
the upper left area with respect to the curve is the possible
convergence region.





















Fig. 7: Iterations versus degradation rate for different home-
destination distances.
VI. CONCLUSION
In this paper, an ant-behavior inspired intelligent NanoNet
is proposed for targeted drug delivery system. It is a real
active drug delivery method, because it does not only rely
on blood vessel circulation. A complete framework for the
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Fig. 8: Iteration versus number of small nanomachines for
different home-destination distances.



























Fig. 9: Maximum molecule release Q versus home-destination
distance N .
whole system is proposed. With the collaboration of simple
intelligence, the path between the home and destination can be
found. The mechanism and algorithm are presented in detail.
The convergence performance is analytically discussed and
validated by simulations. The influence of key factors such
as molecule degradation rate to the convergence performance
is evaluated. Future work would take different edge weights
of the graph into account and analyze the corresponding
convergence performance.
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